surgoncoКреативная хирургия и онкологияCreative surgery and oncology2076-30932307-0501Башкирский государственный медицинский университет10.24060/2076-3093-2020-10-4-319-329surgonco-536Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWSОсобенности метастазирования рака яичникаSpecific Features of Ovarian Cancer Metastasishttps://orcid.org/0000-0002-4091-382XМустафинР. Н.MustafinR. N.ruji79@mail.ruХаликоваЛ. В.KhalikovaL. V.
кафедра гистологииУфа
https://orcid.org/0000-0003-2987-3334ХуснутдиноваЭ. К.KhusnutdinovaE. K.Башкирский государственный медицинский университетРоссияBashkir State Medical UniversityRussian FederationИнститут биохимии и генетики Уфимского федерального исследовательского центра РАНRussian FederationInstitute of Biochemistry & Genetics of Ufa Science Centre of the RASRussian Federation202030122020104319329Copyright © Мустафин Р.Н., Халикова Л.В., Хуснутдинова Э.К., 20202020Мустафин Р.Н., Халикова Л.В., Хуснутдинова Э.К.Mustafin R.N., Khalikova L.V., Khusnutdinova E.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.surgonco.ru/jour/article/view/536рак яичникабольшой сальникканцероматозлимфоцитыметастазымлечные пятнагенная экспрессияovarian cancergreater omentumcarcinomatosislymphocytesmetastasesmilky spotsgene expressionReferencesStewart C., Ralyea C., Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35(2):151–6. DOI: 10.1016/j.soncn.2019.02.001Stewart C., Ralyea C., Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35(2):151–6. DOI: 10.1016/j.soncn.2019.02.001Yeung T.L., Leung C.S., Yip K.P., Au Yeung C.L., Wong S.T., Mok S.C. Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis. Am J Physiol Cell Physiol. 2015;309(7):C444–56. DOI: 10.1152/ajpcell.00188.2015Yeung T.L., Leung C.S., Yip K.P., Au Yeung C.L., Wong S.T., Mok S.C. Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis. Am J Physiol Cell Physiol. 2015;309(7):C444–56. DOI: 10.1152/ajpcell.00188.2015Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177(3):1053–64. DOI: 10.2353/ajpath.2010.100105Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177(3):1053–64. DOI: 10.2353/ajpath.2010.100105Weidle U.H., Birzele F., Kollmorgen G., Rueger R. Mechanisms and targets involved in dissemination of ovarian cancer. Cancer Genomics Proteomics. 2016;13(6):407–23. DOI: 10.21873/cgp.20004Weidle U.H., Birzele F., Kollmorgen G., Rueger R. Mechanisms and targets involved in dissemination of ovarian cancer. Cancer Genomics Proteomics. 2016;13(6):407–23. DOI: 10.21873/cgp.20004Krishnan V., Clark R., Chekmareva M., Johnson A., George S., Shaw P., et al. In vivo and ex vivo approaches to study ovarian cancer metastatic colonization of milky spot structures in peritoneal adipose. J Vis Exp. 2015;(105):e52721. DOI: 10.3791/52721Krishnan V., Clark R., Chekmareva M., Johnson A., George S., Shaw P., et al. In vivo and ex vivo approaches to study ovarian cancer metastatic colonization of milky spot structures in peritoneal adipose. J Vis Exp. 2015;(105):e52721. DOI: 10.3791/52721Sorensen E.W., Gerber S.A., Sedlacek A.L., Rybalko V.Y., Chan W.M., Lord E.M. Omental immune aggregates and tumor metastasis within the peritoneal cavity. Immunol Res. 2009;45(2–3):185–94. DOI: 10.1007/s12026-009-8100-2Sorensen E.W., Gerber S.A., Sedlacek A.L., Rybalko V.Y., Chan W.M., Lord E.M. Omental immune aggregates and tumor metastasis within the peritoneal cavity. Immunol Res. 2009;45(2–3):185–94. DOI: 10.1007/s12026-009-8100-2Gerber S.A., Rybalko V.Y., Bigelow C.E., Lugade A.A., Foster T.H., Frelinger J.G., et al. Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol. 2006;169(5):1739–52. DOI: 10.2353/ajpath.2006.051222Gerber S.A., Rybalko V.Y., Bigelow C.E., Lugade A.A., Foster T.H., Frelinger J.G., et al. Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol. 2006;169(5):1739–52. DOI: 10.2353/ajpath.2006.051222Meza-Perez S., Randall T.D. Immunological functions of the omentum. Trends Immunol. 2017;38(7):526–36. DOI: 10.1016/j.it.2017.03.002Meza-Perez S., Randall T.D. Immunological functions of the omentum. Trends Immunol. 2017;38(7):526–36. DOI: 10.1016/j.it.2017.03.002Liu J., Geng X., Li Y. Milky spots: omental functional units and hotbeds for peritoneal cancer metastasis. Tumor Biol. 2016;37:5715–26. DOI: 10.1007/s13277-016-4887-3Liu J., Geng X., Li Y. Milky spots: omental functional units and hotbeds for peritoneal cancer metastasis. Tumor Biol. 2016;37:5715–26. DOI: 10.1007/s13277-016-4887-3Clark R., Krishnan V., Schoof M., Rodriguez I., Theriault B., Chekmareva M., et al. Milky spots promote ovarian cancer metastatic colonization of peritoneal adipose in experimental models. Am J Pathol. 2013;183(2):576–91. DOI: 10.1016/j.ajpath.2013.04.023Clark R., Krishnan V., Schoof M., Rodriguez I., Theriault B., Chekmareva M., et al. Milky spots promote ovarian cancer metastatic colonization of peritoneal adipose in experimental models. Am J Pathol. 2013;183(2):576–91. DOI: 10.1016/j.ajpath.2013.04.023Ben Arie A., McNally L., Kapp D.S., Teng N.N. The omentum and omentectomy in epithelial ovarian cancer: a reappraisal. Part I. Omental function and history of omentectomy. Gynecol Oncol. 2013;131(3):780–3. DOI: 10.1016/j.ygyno.2013.09.014Ben Arie A., McNally L., Kapp D.S., Teng N.N. The omentum and omentectomy in epithelial ovarian cancer: a reappraisal. Part I. Omental function and history of omentectomy. Gynecol Oncol. 2013;131(3):780–3. DOI: 10.1016/j.ygyno.2013.09.014Arie A.B., McNally L., Kapp D.S., Teng N.N. The omentum and omentectomy in epithelial ovarian cancer: a reappraisal. Part II. The role of omentectomy in the staging and treatment of apparent early stage epithelial ovarian cancer. Gynecol Oncol. 2013;131(3):784–90. DOI: 10.1016/j.ygyno.2013.09.013Arie A.B., McNally L., Kapp D.S., Teng N.N. The omentum and omentectomy in epithelial ovarian cancer: a reappraisal. Part II. The role of omentectomy in the staging and treatment of apparent early stage epithelial ovarian cancer. Gynecol Oncol. 2013;131(3):784–90. DOI: 10.1016/j.ygyno.2013.09.013McNally L., Teng N.N., Kapp D.S., Karam A. Does omentectomy in epithelial ovarian cancer affect survival? An analysis of the Surveillance, Epidemiology, and End Results database. Int J Gynecol Cancer. 2015;25(4):607–15. DOI: 10.1097/IGC.0000000000000412McNally L., Teng N.N., Kapp D.S., Karam A. Does omentectomy in epithelial ovarian cancer affect survival? An analysis of the Surveillance, Epidemiology, and End Results database. Int J Gynecol Cancer. 2015;25(4):607–15. DOI: 10.1097/IGC.0000000000000412Bahar S.G., Rokkam V.R. Omentum Tumors. [Updated 2020 Oct 10]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK563226/Bahar S.G., Rokkam V.R. Omentum Tumors. [Updated 2020 Oct 10]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK563226/Havrlentova L., Faistova H., Mazur M., Ziak D., Polak S. Comparative analysis of human omental milky spots between the patients with colon cancer and the control group. Bratisl Lek Listy. 2017;118(10):580–4. DOI: 10.4149/BLL_2017_111Havrlentova L., Faistova H., Mazur M., Ziak D., Polak S. Comparative analysis of human omental milky spots between the patients with colon cancer and the control group. Bratisl Lek Listy. 2017;118(10):580–4. DOI: 10.4149/BLL_2017_111Cipolletta D., Cohen P., Spiegelman B.M., Benoist C., Mathis D. Appearance and disappearance of the mRNA signature characteristic of Treg cells in visceral adipose tissue: age, diet, and PPARγ effects. Proc Natl Acad Sci USA. 2015;112(2):482–7. DOI: 10.1073/pnas.1423486112Cipolletta D., Cohen P., Spiegelman B.M., Benoist C., Mathis D. Appearance and disappearance of the mRNA signature characteristic of Treg cells in visceral adipose tissue: age, diet, and PPARγ effects. Proc Natl Acad Sci USA. 2015;112(2):482–7. DOI: 10.1073/pnas.1423486112Ke X., Shen L. Targeting cytokines secreted by CD4+ CD25high CD127low regulatory T cells inhibits ovarian cancer progression. Scand J Immunol. 2019;89(2):e12736. DOI: 10.1111/sji.12736Ke X., Shen L. Targeting cytokines secreted by CD4+ CD25high CD127low regulatory T cells inhibits ovarian cancer progression. Scand J Immunol. 2019;89(2):e12736. DOI: 10.1111/sji.12736Krishnan V., Tallapragada S., Schaar B., Kamat K., Chanana A.M., Zhang Y., et al. Omental macrophages secrete chemokine ligands that promote ovarian cancer colonization of the omentum via CCR1. Commun Biol. 2020;3(1):524. DOI: 10.1038/s42003-020-01246-zKrishnan V., Tallapragada S., Schaar B., Kamat K., Chanana A.M., Zhang Y., et al. Omental macrophages secrete chemokine ligands that promote ovarian cancer colonization of the omentum via CCR1. Commun Biol. 2020;3(1):524. DOI: 10.1038/s42003-020-01246-zEtzerodt A., Moulin M., Doktor T.K., Delfini M., Mossadegh-Keller N., Bajenoff M., et al. Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer. J Exp Med. 2020;217(4):e20191869. DOI: 10.1084/jem.20191869Etzerodt A., Moulin M., Doktor T.K., Delfini M., Mossadegh-Keller N., Bajenoff M., et al. Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer. J Exp Med. 2020;217(4):e20191869. DOI: 10.1084/jem.20191869Lee W., Ko S.Y., Mohamed M.S., Kenny H.A., Lengyel E., Naora H. Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. J Exp Med. 2019;216(1):176–94. DOI: 10.1084/jem.20181170Lee W., Ko S.Y., Mohamed M.S., Kenny H.A., Lengyel E., Naora H. Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. J Exp Med. 2019;216(1):176–94. DOI: 10.1084/jem.20181170Zhang Q., Zhou W., Yu S., Ju Y., Kit Yan To S., Sze Tsai Wong A., et al. Metabolic reprogramming of ovarian cancer involves ACSL1-mediated metastasis stimulation through upregulated protein myristoylation. Oncogene. 2021;40:97–111. DOI: 10.1038/s41388-020-01516-4Zhang Q., Zhou W., Yu S., Ju Y., Kit Yan To S., Sze Tsai Wong A., et al. Metabolic reprogramming of ovarian cancer involves ACSL1-mediated metastasis stimulation through upregulated protein myristoylation. Oncogene. 2021;40:97–111. DOI: 10.1038/s41388-020-01516-4Nieman K.M., Kenny H.A., Penicka C.V., Ladanyi A., Buell-Gutbrod R., Zillhardt M.R., et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17(11):1498–503. DOI: 10.1038/nm.2492Nieman K.M., Kenny H.A., Penicka C.V., Ladanyi A., Buell-Gutbrod R., Zillhardt M.R., et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17(11):1498–503. DOI: 10.1038/nm.2492Ladanyi A., Mukherjee A., Kenny H.A., Johnson A., Mitra A.K., Sundaresan S., et al. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 2018;37(17):2285–301. DOI: 10.1038/s41388-017-0093-zLadanyi A., Mukherjee A., Kenny H.A., Johnson A., Mitra A.K., Sundaresan S., et al. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 2018;37(17):2285–301. DOI: 10.1038/s41388-017-0093-zHu J., Liu Z., Wang X. Does TP53 mutation promote ovarian cancer metastasis to omentum by regulating lipid metabolism. Med Hypotheses. 2013;81(4):515–20. DOI: 10.1016/j.mehy.2013.06.009Hu J., Liu Z., Wang X. Does TP53 mutation promote ovarian cancer metastasis to omentum by regulating lipid metabolism. Med Hypotheses. 2013;81(4):515–20. DOI: 10.1016/j.mehy.2013.06.009Cole A.J., Dwight T., Gill A.J., Dickson K.-A., Zhu Y., Clarkson A., et al. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochamistry and massively parallel sequencing. Sci Rep. 2016;6:26191. DOI: 10.1038/srep26191Cole A.J., Dwight T., Gill A.J., Dickson K.-A., Zhu Y., Clarkson A., et al. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochamistry and massively parallel sequencing. Sci Rep. 2016;6:26191. DOI: 10.1038/srep26191McKenzie A.J., Hicks S.R., Svec K.V., Naughton H., Edmunds Z.L., Howe A.K. The mechanical microenvironment regulates ovarian cancer cell morphology, migration, and spheroid disaggregation. Sci Rep. 2018;8(1):7228. DOI: 10.1038/s41598-018-25589-0McKenzie A.J., Hicks S.R., Svec K.V., Naughton H., Edmunds Z.L., Howe A.K. The mechanical microenvironment regulates ovarian cancer cell morphology, migration, and spheroid disaggregation. Sci Rep. 2018;8(1):7228. DOI: 10.1038/s41598-018-25589-0Huang Y.L., Liang C.Y., Ritz D., Coelho R., Septiadi D., Estermann M., et al. Collagen-rich omentum is a premetastatic niche for integrin α2-mediated peritoneal metastasis. Elife. 2020;9:e59442. DOI: 10.7554/eLife.59442Huang Y.L., Liang C.Y., Ritz D., Coelho R., Septiadi D., Estermann M., et al. Collagen-rich omentum is a premetastatic niche for integrin α2-mediated peritoneal metastasis. Elife. 2020;9:e59442. DOI: 10.7554/eLife.59442Nakamura K., Sawada K., Kinose Y., Yoshimura A., Toda A., Nakatsuka E., et al. Exosomes promote ovarian cancer cell invasion through transfer of CD44 to peritoneal mesothelial cells. Mol Cancer Res. 2017;15(1):78–92. DOI: 10.1158/1541-7786.MCR-16-0191Nakamura K., Sawada K., Kinose Y., Yoshimura A., Toda A., Nakatsuka E., et al. Exosomes promote ovarian cancer cell invasion through transfer of CD44 to peritoneal mesothelial cells. Mol Cancer Res. 2017;15(1):78–92. DOI: 10.1158/1541-7786.MCR-16-0191Paschos K.A., Canovas D., Bird N.C. The engagement of selectins and their ligands in colorectal cancer liver metastases. J Cell Mol Med. 2010;14(1-2):165–74. DOI: 10.1111/j.1582-4934.2009.00852.xPaschos K.A., Canovas D., Bird N.C. The engagement of selectins and their ligands in colorectal cancer liver metastases. J Cell Mol Med. 2010;14(1-2):165–74. DOI: 10.1111/j.1582-4934.2009.00852.xWiniarski B.K., Cope N., Alexander M., Pilling L.C., Warren S., Acheson N., et al. Clinical relevance of increased endothelial and mesothelial expression of proangiogenic proteases and VEGFA in the omentum of patients with metastatic ovarian high-grade serous carcinoma. Transl Oncol. 2014;7(2):267–76.e4. DOI: 10.1016/j.tranon.2014.02.013Winiarski B.K., Cope N., Alexander M., Pilling L.C., Warren S., Acheson N., et al. Clinical relevance of increased endothelial and mesothelial expression of proangiogenic proteases and VEGFA in the omentum of patients with metastatic ovarian high-grade serous carcinoma. Transl Oncol. 2014;7(2):267–76.e4. DOI: 10.1016/j.tranon.2014.02.013Wang H., Huang X., Zhang J., Shao N., Chen L.O., Ma D., et al. The expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer. Clin Chim Acta. 2014;436:243– 8. DOI: 10.1016/j.cca.2014.06.005Wang H., Huang X., Zhang J., Shao N., Chen L.O., Ma D., et al. The expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer. Clin Chim Acta. 2014;436:243– 8. DOI: 10.1016/j.cca.2014.06.005Sopo M., Anttila M., Hämäläinen K., Kivelä A., Ylä- Herttuala S., Kosma V.M., et al. Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer. BMC Cancer. 2019;19(1):584. DOI: 10.1186/s12885-019-5757-3Sopo M., Anttila M., Hämäläinen K., Kivelä A., Ylä- Herttuala S., Kosma V.M., et al. Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer. BMC Cancer. 2019;19(1):584. DOI: 10.1186/s12885-019-5757-3Roggiani F., Mezzanzanica D., Rea K., Tomassetti A. Guidance of signaling activations by cadherins and integrins in epithelial ovarian cancer cells. Int J Mol Sci. 2016;17(9):1387. DOI: 10.3390/ijms17091387Roggiani F., Mezzanzanica D., Rea K., Tomassetti A. Guidance of signaling activations by cadherins and integrins in epithelial ovarian cancer cells. Int J Mol Sci. 2016;17(9):1387. DOI: 10.3390/ijms17091387Mui K.L., Chen C.S., Assoian R.K. The mechanical regulation of integrin-cadherin crosstalk organizes cells, signaling and forces. J Cell Sci. 2016;129(6):1093–100. DOI: 10.1242/jcs.183699Mui K.L., Chen C.S., Assoian R.K. The mechanical regulation of integrin-cadherin crosstalk organizes cells, signaling and forces. J Cell Sci. 2016;129(6):1093–100. DOI: 10.1242/jcs.183699Makrilia N., Kollias A., Manolopoulos L., Syrigos K. Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest. 2009;27(10):1023–37. DOI: 10.3109/07357900902769749Makrilia N., Kollias A., Manolopoulos L., Syrigos K. Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest. 2009;27(10):1023–37. DOI: 10.3109/07357900902769749Yi Y., Cheng J.C., Klausen C., Leung P.C.K. Activin A promotes ovarian cancer cell migration by suppressing E-cadherin expression. Exp Cell Res. 2019;382(2):111471. DOI: 10.1016/j.yexcr.2019.06.016Yi Y., Cheng J.C., Klausen C., Leung P.C.K. Activin A promotes ovarian cancer cell migration by suppressing E-cadherin expression. Exp Cell Res. 2019;382(2):111471. DOI: 10.1016/j.yexcr.2019.06.016Janiszewska M., Primi M.C., Izard T. Cell adhesion in cancer: Beyond the migration of single cells. J Biol Chem. 2020;295(8):2495–05. DOI: 10.1074/jbc.REV119.007759Janiszewska M., Primi M.C., Izard T. Cell adhesion in cancer: Beyond the migration of single cells. J Biol Chem. 2020;295(8):2495–05. DOI: 10.1074/jbc.REV119.007759Wong C.W., Dye D.E., Coombe D.R. The role of immunoglobulin superfamily cell adhesion molecules in cancer metastasis. Int J Cell Biol. 2012; 2012:340296. DOI: 10.1155/2012/340296Wong C.W., Dye D.E., Coombe D.R. The role of immunoglobulin superfamily cell adhesion molecules in cancer metastasis. Int J Cell Biol. 2012; 2012:340296. DOI: 10.1155/2012/340296Borsig L. Selectins in cancer immunity. Glycobiology. 2018;28(9):648–55. DOI: 10.1093/glycob/cwx105Borsig L. Selectins in cancer immunity. Glycobiology. 2018;28(9):648–55. DOI: 10.1093/glycob/cwx105Khaustova N.A., Maltseva D.V., Oliveira-Ferrer L., Stürken C., MildeLangosch K., Makarova J.A., et al. Selectin-independent adhesion during ovarian cancer metastasis. Biochimie. 2017;142:197–206. DOI: 10.1016/j.biochi.2017.09.009Khaustova N.A., Maltseva D.V., Oliveira-Ferrer L., Stürken C., MildeLangosch K., Makarova J.A., et al. Selectin-independent adhesion during ovarian cancer metastasis. Biochimie. 2017;142:197–206. DOI: 10.1016/j.biochi.2017.09.009Carroll M.J., Fogg K.C., Patel H.A., Krause H.B., Mancha A.S., Patankar M.S., et al. Alternatively-activated macrophages upregulate mesothelial expression of P-selectin to enhance adhesion of ovarian cancer cells. Cancer Res. 2018;78(13):3560–73. DOI: 10.1158/0008-5472.CAN-17-3341Carroll M.J., Fogg K.C., Patel H.A., Krause H.B., Mancha A.S., Patankar M.S., et al. Alternatively-activated macrophages upregulate mesothelial expression of P-selectin to enhance adhesion of ovarian cancer cells. Cancer Res. 2018;78(13):3560–73. DOI: 10.1158/0008-5472.CAN-17-3341Rangel-Moreno J., Moyron-Quiroz J.E., Carragher D.M., Kusser K., Hartson L., Moquin A., et al. Omental milky spots develop in the absence of lymphoid tissue-inducer cells and support B and T cell responses to peritoneal antigens. Immunity. 2009;30(5):731–43. DOI: 10.1016/j.immuni.2009.03.014Rangel-Moreno J., Moyron-Quiroz J.E., Carragher D.M., Kusser K., Hartson L., Moquin A., et al. Omental milky spots develop in the absence of lymphoid tissue-inducer cells and support B and T cell responses to peritoneal antigens. Immunity. 2009;30(5):731–43. DOI: 10.1016/j.immuni.2009.03.014Martinez F.O., Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;6:13. DOI: 10.12703/P6-13Martinez F.O., Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;6:13. DOI: 10.12703/P6-13Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–13. DOI: 10.1056/NEJMoa020177Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–13. DOI: 10.1056/NEJMoa020177Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005;102(51):18538–43. DOI: 10.1073/pnas.0509182102Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005;102(51):18538–43. DOI: 10.1073/pnas.0509182102Wouters M.C., Komdeur F.L., Workel H.H., Klip H.G., Plat A., Kooi N.M., et al. Treatment regimen, surgical outcome, and T-cell differentiation influence prognostic benefit of tumor-infiltrating lymphocytes in high-grade serous ovarian cancer. Clin Cancer Res. 2016;22(3):714–24. DOI: 10.1158/1078-0432.CCR-15-1617Wouters M.C., Komdeur F.L., Workel H.H., Klip H.G., Plat A., Kooi N.M., et al. Treatment regimen, surgical outcome, and T-cell differentiation influence prognostic benefit of tumor-infiltrating lymphocytes in high-grade serous ovarian cancer. Clin Cancer Res. 2016;22(3):714–24. DOI: 10.1158/1078-0432.CCR-15-1617Pinto M.P., Balmaceda C., Bravo M.L., Kato S., Villarroel A., Owen G.I., et al. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in highgrade serous ovarian cancer. Gynecol Oncol. 2018;151(1):10–7. DOI: 10.1016/j.ygyno.2018.07.025Pinto M.P., Balmaceda C., Bravo M.L., Kato S., Villarroel A., Owen G.I., et al. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in highgrade serous ovarian cancer. Gynecol Oncol. 2018;151(1):10–7. DOI: 10.1016/j.ygyno.2018.07.025Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15. DOI: 10.1038/nature10166Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15. DOI: 10.1038/nature10166Horikawa N., Abiko K., Matsumura N., Hamanishi J., Baba T., Yamaguchi K., et al. Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells. Clin Cancer Res. 2017;23(2):587–99. DOI: 10.1158/1078-0432.CCR-16-0387Horikawa N., Abiko K., Matsumura N., Hamanishi J., Baba T., Yamaguchi K., et al. Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells. Clin Cancer Res. 2017;23(2):587–99. DOI: 10.1158/1078-0432.CCR-16-0387Van der Meer J.M.R., Maas R.J.A., Guldevall K., Klarenaar K., de Jonge P.K.J.D., Evert J.S.H., et al. IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells. Cancer Immunol Immunother. 2020 Nov 3. DOI: 10.1007/s00262-020-02749-8Van der Meer J.M.R., Maas R.J.A., Guldevall K., Klarenaar K., de Jonge P.K.J.D., Evert J.S.H., et al. IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells. Cancer Immunol Immunother. 2020 Nov 3. DOI: 10.1007/s00262-020-02749-8Hoogstad-van Evert J.S., Cany J., van den Brand D., Oudenampsen M., Brock R., Torensma R., et al. Umbilical cord blood CD34+ progenitorderived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD/SCID/IL2Rgnull mice. Oncoimmunology. 2017;6(8):e1320630. DOI: 10.1080/2162402X.2017.1320630Hoogstad-van Evert J.S., Cany J., van den Brand D., Oudenampsen M., Brock R., Torensma R., et al. Umbilical cord blood CD34+ progenitorderived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD/SCID/IL2Rgnull mice. Oncoimmunology. 2017;6(8):e1320630. DOI: 10.1080/2162402X.2017.1320630Pearce O.M.T., Delaine-Smith R.M., Maniati E., Nichols S., Wang J., Böhm S., et al. Deconstruction of a metastatic tumor microenvironment reveals a common matrix response in human cancers. Cancer Discov. 2018;8(3):304–19. DOI: 10.1158/2159-8290.CD-17-0284Pearce O.M.T., Delaine-Smith R.M., Maniati E., Nichols S., Wang J., Böhm S., et al. Deconstruction of a metastatic tumor microenvironment reveals a common matrix response in human cancers. Cancer Discov. 2018;8(3):304–19. DOI: 10.1158/2159-8290.CD-17-0284He L., Wang Q., Zhao X. Microvessel density as a prognostic factor in ovarian cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2015;16(3):869–74. DOI: 10.7314/apjcp.2015.16.3.869He L., Wang Q., Zhao X. Microvessel density as a prognostic factor in ovarian cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2015;16(3):869–74. DOI: 10.7314/apjcp.2015.16.3.869Qiu H., Cao L., Wang D., Xu H., Liang Z. High levels of circulating CD34+/VEGFR3+ lymphatic/vascular endothelial progenitor cells is correlated with lymph node metastasis in patients with epithelial ovarian cancer. J Obstet Gynaecol Res. 2013;39(7):1268–75. DOI: 10.1111/jog.12047Qiu H., Cao L., Wang D., Xu H., Liang Z. High levels of circulating CD34+/VEGFR3+ lymphatic/vascular endothelial progenitor cells is correlated with lymph node metastasis in patients with epithelial ovarian cancer. J Obstet Gynaecol Res. 2013;39(7):1268–75. DOI: 10.1111/jog.12047Rea K., Roggiani F., De Cecco L., Raspagliesi F., Carcangiu M.L., NairMenon J., et al. Simultaneous E- cadherin and PLEKHA7 expression negatively affects E-cadherin/EGFR mediated ovarian cancer cell growth. J Exp Clin Cancer Res. 2018;37(1):146. DOI: 10.1186/s13046-018-0796-1Rea K., Roggiani F., De Cecco L., Raspagliesi F., Carcangiu M.L., NairMenon J., et al. Simultaneous E-cadherin and PLEKHA7 expression negatively affects E-cadherin/EGFR mediated ovarian cancer cell growth. J Exp Clin Cancer Res. 2018;37(1):146. DOI: 10.1186/s13046-018-0796-1Köbel M., Kang E.Y. The many uses of p53 immunohistochemistry in gynecological pathology: proceedings of the ISGyP companion society session at the 2020 USCAP Annual9 Meeting. Int J Gynecol Pathol. 2021;40(1):32–40. DOI: 10.1097/PGP.0000000000000725Köbel M., Kang E.Y. The many uses of p53 immunohistochemistry in gynecological pathology: proceedings of the ISGyP companion society session at the 2020 USCAP Annual9 Meeting. Int J Gynecol Pathol. 2021;40(1):32–40. DOI: 10.1097/PGP.0000000000000725Mayoral M., Paredes P., Saco A., Fusté P., Perlaza P., Tapias A., et al. Correlation of 18F-FDG uptake on PET/CT with Ki67 immunohistochemistry in pre-treatment epithelial ovarian cancer. Rev Esp Med Nucl Imagen Mol. 2018;37(2):80–6. DOI: 10.1016/j.remn.2017.07.005Mayoral M., Paredes P., Saco A., Fusté P., Perlaza P., Tapias A., et al. Correlation of 18F-FDG uptake on PET/CT with Ki67 immunohistochemistry in pre-treatment epithelial ovarian cancer. Rev Esp Med Nucl Imagen Mol. 2018;37(2):80–6. DOI: 10.1016/j.remn.2017.07.005Li L.T., Jiang G., Chen Q., Zheng J.N. Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 2015;11(3):1566–72. DOI: 10.3892/mmr.2014.2914Li L.T., Jiang G., Chen Q., Zheng J.N. Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 2015;11(3):1566–72. DOI: 10.3892/mmr.2014.2914Ikehara Y., Shiuchi N., Kabata-Ikehara S., Nakanishi H., Yokoyama N., Takagi H., et al. Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells. Cancer Lett. 2008;260(1–2):137–45. DOI: 10.1016/j.canlet.2007.10.038Ikehara Y., Shiuchi N., Kabata-Ikehara S., Nakanishi H., Yokoyama N., Takagi H., et al. Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells. Cancer Lett. 2008;260(1–2):137–45. DOI: 10.1016/j.canlet.2007.10.038Wall J.A., Meza-Perez S., Scalise C.B., Katre A., Londoño A.I., Turbitt W.J., et al. Manipulating the Wnt/β- catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy. Gynecol Oncol. 2021;160(1):285–94. DOI: 10.1016/j.ygyno.2020.10.031Wall J.A., Meza-Perez S., Scalise C.B., Katre A., Londoño A.I., Turbitt W.J., et al. Manipulating the Wnt/β- catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy. Gynecol Oncol. 2021;160(1):285–94. DOI: 10.1016/j.ygyno.2020.10.031
The authors declare that there are no conflicts of interest present.